Race and Insurance Differences in the Receipt of Adjuvant Chemotherapy Among Patients With Stage III Colon Cancer
- 10 August 2015
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (23) , 2530-2536
Abstract
Purpose: Although the incidence and mortality of colon cancer in the United States has declined over the past two decades, blacks have worse outcomes than whites. Variations in treatment may contribute to mortality differentials. Methods: Patients diagnosed with stage III colon cancer were randomly sampled from the SEER program from the years 1990, 1991, 1995, 2000, 2005, and 2010. Patients were categorized as non-Hispanic white (n = 835) or black (n = 384). Treatment data were obtained from a review of the medical records, and these data were verified through contact with the original treating physicians. Log-binomial regression models were used to estimate the association between race and receipt of adjuvant chemotherapy. Effect modification by insurance was assessed with use of single referent models. Results: Receipt of adjuvant chemotherapy among both white and black patients increased from the period encompassing the years 1990 and 1991 (white, 58%; black, 45%) to the year 2005 (white, 72%; black, 71%) and then decreased in the year 2010 (white, 66%; black, 57%). There were marked racial disparities in the time period of 1990 to 1991 and again in 2010, with black patients less likely to receive adjuvant chemotherapy as compared with white patients (risk ratio [RR], .82; 95% CI, .72 to .93). For black patients, receipt of adjuvant chemotherapy did not differ across insurance categories (RR for private insurance, .80; 95% CI, .69 to .93; RR for Medicare, .84; 95% CI, .69 to 1.02; and RR for Medicaid, .84; 95% CI, .69 to 1.02), although a larger proportion had Medicaid in all years of the study as compared with white patients. Conclusion: The chemotherapy differential narrowed after the time period of 1990 to 1991, but our findings suggest that the disparity reemerged in 2010. Recent decreases in chemotherapy use may be due, in part, to the economic downturn and an increase in Medicaid coverage.Keywords
This publication has 57 references indexed in Scilit:
- Contribution of Screening and Survival Differences to Racial Disparities in Colorectal Cancer RatesCancer Epidemiology, Biomarkers & Prevention, 2012
- Economic Burden of Cancer in the United States: Estimates, Projections, and Future ResearchCancer Epidemiology, Biomarkers & Prevention, 2011
- Trends in Colorectal Cancer Test Use among Vulnerable Populations in the United StatesCancer Epidemiology, Biomarkers & Prevention, 2011
- Projections of the Cost of Cancer Care in the United States: 2010-2020JNCI: Journal of the National Cancer Institute, 2011
- Out of pocket cost comparison between Caucasian and minority breast cancer survivors in the Breast Cancer Education Intervention (BCEI)Breast Cancer Research and Treatment, 2010
- Forgoing medical care because of costCancer, 2010
- Race and Colorectal Cancer Disparities: Health-Care Utilization vs Different Cancer SusceptibilitiesJNCI: Journal of the National Cancer Institute, 2010
- Cost disparities in lung cancer treatment by disability status, sex, and raceDisability and Health Journal, 2008
- Racial disparities in cancer therapyCancer, 2008
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987